Plavix

clopidogrel

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Plavix. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Plavix.

What is Plavix?

Plavix is a medicine that contains the active substance clopidogrel. It is available as pink tablets (round: 75 mg; oblong: 300 mg).

What is Plavix used for?

Plavix is used to prevent problems caused by blood clots in adults who have:

  • recently had a myocardial infarction (heart attack). Plavix can be started between a few days and 35 days after the attack;
  • recently had an ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). Plavix can be started between seven days and six months after the stroke;
  • peripheral arterial disease (problems with blood flow in the arteries);
  • a condition known as ‘acute coronary syndrome’, when it should be given with aspirin (another medicine that prevents blood clots). Acute coronary syndrome is a group of heart problems that include heart attacks and unstable angina (a severe type of chest pain). Some of these patients may have had a stent (a short tube) placed in an artery to prevent it from closing up.
  • atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin. It is used in those patients who have at least one risk factor for vascular events such as a heart attack or stroke, cannot take vitamin-K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.

The medicine can only be obtained with a prescription.

How is Plavix used?

The standard dose of Plavix is one 75-mg tablet once a day. In acute coronary syndrome, treatment generally starts with a loading dose of one 300-mg tablet or four 75-mg tablets. This is then followed by the standard 75-mg dose once a day for at least four weeks (in ‘ST-segment-elevation’ myocardial infarction) or for up to 12 months (in unstable angina or ‘non-Q-wave’ myocardial infarction). In acute coronary syndrome and atrial fibrillation, Plavix is used together with aspirin, the dose of which should not be higher than 100 mg.

Plavix is converted into its active form in the body. For genetic reasons, some patients may not be able to convert Plavix as effectively as others, which could reduce their response to the medicine. The best dose to use in these patients has not yet been determined.

How does Plavix work?

The active substance in Plavix, clopidogrel, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together). Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. This stops the platelets becoming ‘sticky’, reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.

How has Plavix been studied?

Plavix has been compared with aspirin in a study called CAPRIE including around 19,000 patients who had recently had a heart attack or an ischaemic stroke, or who had established peripheral arterial disease. The main measure of effectiveness was how many patients experienced a new ‘ischaemic event’ (heart attack, ischaemic stroke or death) over one to three years.

In acute coronary syndrome, Plavix has been compared with placebo (a dummy treatment) in one study involving over 12,000 patients with non-ST-segment elevation, 2,172 of whom had a stent inserted during the study (CURE study, lasting up to a year). Plavix has also been compared with placebo in two studies involving patients with ST-segment elevation: CLARITY, which involved over 3,000 patients and lasted up to eight days; and COMMIT, which involved almost 46,000 patients and in which the patients received Plavix with or without metoprolol (another medicine used for heart problems or high blood pressure) for up to four weeks. In the studies of acute coronary syndrome, all of the patients also took aspirin and the main measure of effectiveness was the number of patients who experienced an ‘event’ such as a blocked artery, another heart attack or death during the study.

In atrial fibrillation, Plavix has been compared with placebo (both taken together with aspirin) in one main study involving around 7,500 patients who had at least one risk factor for vascular events and who could not take vitamin-K-antagonist therapy. The patients were treated for an average of three years, and the main measure of effectiveness was the number of patients who experienced an ‘event’ such as a heart attack, ischaemic stroke or death.

What benefit has Plavix shown during the studies?

Plavix was more effective than aspirin at preventing new ischaemic events. In CAPRIE, there were 939 events in the Plavix group, and 1,020 in the aspirin group. This corresponds to a relative reduction in risk of 9% compared with aspirin. This means that fewer patients will have new ischaemic events if they receive Plavix than if they receive aspirin. In other words, about 10 patients in 1,000 will avoid having a new ischaemic event two years after starting Plavix instead of aspirin.

In non-ST-segment-elevation acute coronary syndrome, the overall relative reduction in the risk of an event compared with placebo was 20%. There was also a reduction in the patients who had a stent inserted. In ST-segment-elevation myocardial infarction, fewer patients on Plavix had events than patients on placebo (262 against 377 in the CLARITY study, and 2,121 against 2,310 in the COMMIT study). This showed that Plavix reduces the risk of an event.

In the study in atrial-fibrillation patients, Plavix taken together with aspirin reduced the risk of new events by 11% compared with placebo taken with aspirin, with the largest reduction (28%) seen for stroke.

What is the risk associated with Plavix?

The most common side effects with Plavix (seen in between 1 and 10 patients in 100) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising and bleeding where the skin is punctured. For the full list of all side effects reported with Plavix, see the package leaflet.

Plavix should not be used in people who may be hypersensitive (allergic) to clopidogrel or any of the other ingredients. It must not be used in patients who have severe liver disease or a disease that may cause bleeding such as a stomach ulcer or bleeding in the brain.

Why has Plavix been approved?

The CHMP decided that Plavix’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Other information about Plavix

The European Commission granted a marketing authorisation valid throughout the European Union for Plavix to Sanofi Pharma Bristol-Myers Squibb SNC on 15 July 1998. The marketing authorisation is valid for an unlimited period.

For more information about treatment with Plavix, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Plavix : EPAR - Summary for the public BG = bălgarski 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public ES = español 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public CS = čeština 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public DA = dansk 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public DE = Deutsch 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public ET = eesti keel 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public EL = elliniká 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public EN = English 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public FR = français 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public IT = italiano 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public LV = latviešu valoda 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public LT = lietuvių kalba 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public HU = magyar 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public MT = Malti 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public NL = Nederlands 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public PL = polski 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public PT = português 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public RO = română 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public SK = slovenčina 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public SL = slovenščina 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public FI = suomi 2009-10-13 2011-04-01
Plavix : EPAR - Summary for the public SV = svenska 2009-10-13 2011-04-01

This EPAR was last updated on 27/01/2016 .

Authorisation details

Product details

Product details for Plavix
NamePlavix
Agency product numberEMEA/H/C/000174
Active substance

clopidogrel hydrogen sulfate

International non-proprietary name (INN) or common name

clopidogrel

Therapeutic area Peripheral Vascular DiseasesStrokeAcute Coronary SyndromeMyocardial InfarctionAtrial Fibrillation
Anatomical therapeutic chemical (ATC) code B01AC04

Publication details

Publication details for Plavix
Marketing-authorisation holder

Sanofi Clir SNC

Revision32
Date of issue of marketing authorisation valid throughout the European Union15/07/1998

Contact address:

Sanofi Clir SNC
54, rue La Boétie
F-75008 Paris
France

Product information

Product information

10/12/2015  Plavix -EMEA/H/C/000174 -IAIN/0122

Name Language First published Last updated
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27
Plavix : EPAR - Product Information SV = svenska 2009-10-13 2016-01-27

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27
Plavix : EPAR - All Authorised presentations SV = svenska 2008-11-05 2010-05-27

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Prevention of atherothrombotic events

Clopidogrel is indicated in:

  • adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;
  • adult patients suffering from acute coronary syndrome:
    • non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);
    • ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.

Prevention of atherothrombotic and thromboembolic events in atrial fibrillation

In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

Assessment History

Changes since initial authorisation of medicine

Initial marketing-authorisation documents

Name Language First published Last updated
Plavix : EPAR - Procedural steps taken before authorisation SV = svenska 2006-10-24  
Plavix : EPAR - Scientific Discussion SV = svenska 2006-10-24  

Authorised

This medicine is approved for use in the European Union

More information on Plavix